Top-down treatment of newly diagnosed Crohn’s could be a game changer: study
Top-down treatment should be standard care for newly diagnosed patients, the authors said.
Patients with Crohn’s disease who start on infliximab combined with an immunomodulator have far better outcomes within a year compared with traditional ‘step-up’ treatment, a UK trial shows.
The findings are “potentially transformative” for managing newly diagnosed patients, the study authors report, with early combination therapy more likely to result in long-term steroid-free and surgery-free remission.
